U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H14O4S
Molecular Weight 314.3574
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ROFECOXIB

SMILES

CS(=O)(=O)c1ccc(cc1)C2=C(c3ccccc3)C(=O)OC2

InChI

InChIKey=RZJQGNCSTQAWON-UHFFFAOYSA-N
InChI=1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3

HIDE SMILES / InChI

Molecular Formula C17H14O4S
Molecular Weight 314.3574
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Rofecoxib is a nonsteroidal anti-inflammatory drug which selectively inhibits COX-2 and subsequent prostaglandin synthesis. The drug was developed by Merk and approved by FDA in 1999 for relief of signs and symptoms of arthritis, acute pain in adults, and painful menstrual cycles under the name Vioxx. Later on Merck voluntarily withdrawn Vioxx from the market due to safety concerns (high risk of heart attack and stroke).

CNS Activity

Curator's Comment:: Rofecoxib has been shown to cross the blood-brain barrier in rats.

Originator

Curator's Comment:: # Merck

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.02 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Palliative
VIOXX

Approved Use

For relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis in adults, pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older and who weigh 10 kg (22 lbs) or more, for the management of acute pain in adults, for the treatment of primary dysmenorrhea, for the acute treatment of migraine attacks with or without aura in adults.

Launch Date

9.2715837E11
Palliative
VIOXX

Approved Use

For relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis in adults, pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older and who weigh 10 kg (22 lbs) or more, for the management of acute pain in adults, for the treatment of primary dysmenorrhea, for the acute treatment of migraine attacks with or without aura in adults.

Launch Date

9.2715837E11
Primary
VIOXX

Approved Use

For relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis in adults, pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older and who weigh 10 kg (22 lbs) or more, for the management of acute pain in adults, for the treatment of primary dysmenorrhea, for the acute treatment of migraine attacks with or without aura in adults.

Launch Date

9.2715837E11
Primary
VIOXX

Approved Use

For relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis in adults, pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older and who weigh 10 kg (22 lbs) or more, for the management of acute pain in adults, for the treatment of primary dysmenorrhea, for the acute treatment of migraine attacks with or without aura in adults.

Launch Date

9.2715837E11
Primary
VIOXX

Approved Use

For relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis in adults, pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older and who weigh 10 kg (22 lbs) or more, for the management of acute pain in adults, for the treatment of primary dysmenorrhea, for the acute treatment of migraine attacks with or without aura in adults.

Launch Date

9.2715837E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
321 ng/mL
25 mg 1 times / day multiple, oral
dose: 25 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ROFECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4018 ng × h/mL
25 mg 1 times / day multiple, oral
dose: 25 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ROFECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
17 h
25 mg 1 times / day multiple, oral
dose: 25 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ROFECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
13%
25 mg 1 times / day multiple, oral
dose: 25 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ROFECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
12.5 mg 1 times / day steady, oral
Recommended
Dose: 12.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 12.5 mg, 1 times / day
Co-administed with::
Gefitinib(250 mg)
Sources:
unhealthy, 44-76 years
n = 6
Health Status: unhealthy
Condition: non small-cell lung cancer
Age Group: 44-76 years
Sex: M+F
Population Size: 6
Sources:
Disc. AE: Renal impairment...
AEs leading to
discontinuation/dose reduction:
Renal impairment (grade 1, 1 patient)
Sources:
50 mg 1 times / day steady, oral
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Co-administed with::
Gefitinib(250 mg)
Sources:
unhealthy, 44-76 years
n = 33
Health Status: unhealthy
Condition: non small-cell lung cancer
Age Group: 44-76 years
Sex: M+F
Population Size: 33
Sources:
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
unhealthy, 58–71years
n = 1167
Health Status: unhealthy
Condition: colorectal cancer
Age Group: 58–71years
Sex: M+F
Population Size: 1167
Sources:
Disc. AE: Cardiac thrombosis...
Other AEs: Cardiac thrombosis...
AEs leading to
discontinuation/dose reduction:
Cardiac thrombosis (grade 5, 4 patients)
Other AEs:
Cardiac thrombosis (16 patients)
Sources:
25 mg 1 times / day multiple, oral (max)
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, 66.8 years
n = 2896
Health Status: unhealthy
Condition: painful osteoarthritis of the knee or hip
Age Group: 66.8 years
Sex: M+F
Population Size: 2896
Sources:
Disc. AE: Dyspepsia, Nausea...
AEs leading to
discontinuation/dose reduction:
Dyspepsia (4.4%)
Nausea (2.4%)
Dizziness (2.1%)
Sources:
25 mg 1 times / day multiple, oral (typical)
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, adult
n = 2200000
Health Status: unhealthy
Condition: various
Age Group: adult
Sex: M+F
Population Size: 2200000
Sources:
Disc. AE: Death...
Other AEs: Hemorrhage, Edema...
AEs leading to
discontinuation/dose reduction:
Death (grade 5, 1653 patients)
Other AEs:
Hemorrhage (3915 patients)
Edema (3677 patients)
Thrombosis (1917 patients)
Embolism (233 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Renal impairment grade 1, 1 patient
Disc. AE
12.5 mg 1 times / day steady, oral
Recommended
Dose: 12.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 12.5 mg, 1 times / day
Co-administed with::
Gefitinib(250 mg)
Sources:
unhealthy, 44-76 years
n = 6
Health Status: unhealthy
Condition: non small-cell lung cancer
Age Group: 44-76 years
Sex: M+F
Population Size: 6
Sources:
Cardiac thrombosis 16 patients
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
unhealthy, 58–71years
n = 1167
Health Status: unhealthy
Condition: colorectal cancer
Age Group: 58–71years
Sex: M+F
Population Size: 1167
Sources:
Cardiac thrombosis grade 5, 4 patients
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
unhealthy, 58–71years
n = 1167
Health Status: unhealthy
Condition: colorectal cancer
Age Group: 58–71years
Sex: M+F
Population Size: 1167
Sources:
Dizziness 2.1%
Disc. AE
25 mg 1 times / day multiple, oral (max)
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, 66.8 years
n = 2896
Health Status: unhealthy
Condition: painful osteoarthritis of the knee or hip
Age Group: 66.8 years
Sex: M+F
Population Size: 2896
Sources:
Nausea 2.4%
Disc. AE
25 mg 1 times / day multiple, oral (max)
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, 66.8 years
n = 2896
Health Status: unhealthy
Condition: painful osteoarthritis of the knee or hip
Age Group: 66.8 years
Sex: M+F
Population Size: 2896
Sources:
Dyspepsia 4.4%
Disc. AE
25 mg 1 times / day multiple, oral (max)
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, 66.8 years
n = 2896
Health Status: unhealthy
Condition: painful osteoarthritis of the knee or hip
Age Group: 66.8 years
Sex: M+F
Population Size: 2896
Sources:
Thrombosis 1917 patients
25 mg 1 times / day multiple, oral (typical)
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, adult
n = 2200000
Health Status: unhealthy
Condition: various
Age Group: adult
Sex: M+F
Population Size: 2200000
Sources:
Embolism 233 patients
25 mg 1 times / day multiple, oral (typical)
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, adult
n = 2200000
Health Status: unhealthy
Condition: various
Age Group: adult
Sex: M+F
Population Size: 2200000
Sources:
Edema 3677 patients
25 mg 1 times / day multiple, oral (typical)
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, adult
n = 2200000
Health Status: unhealthy
Condition: various
Age Group: adult
Sex: M+F
Population Size: 2200000
Sources:
Hemorrhage 3915 patients
25 mg 1 times / day multiple, oral (typical)
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, adult
n = 2200000
Health Status: unhealthy
Condition: various
Age Group: adult
Sex: M+F
Population Size: 2200000
Sources:
Death grade 5, 1653 patients
Disc. AE
25 mg 1 times / day multiple, oral (typical)
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, adult
n = 2200000
Health Status: unhealthy
Condition: various
Age Group: adult
Sex: M+F
Population Size: 2200000
Sources:
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
likely
weak (co-administration study)
Comment: A 30% interactions, additional studies would be necessary reduction of the AUC of the CYP3A4 substrate to more completely elucidate the drug interaction midazolam was observed with rofecoxib 25mg profile of rofecoxib and determine the clinical rele- daily. This reduction is most probably due to in- vance of any possible interactions. creased first-pass metabolism through induction of intestinal CYP3A4 by rofecoxib
Page: 4.0
no
no
no
no
yes [IC50 1.17 uM]
Drug as victim
PubMed

PubMed

TitleDatePubMed
Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis.
1999 Jun 22
Rofecoxib.
2000 Jul
Potential adverse effects of cyclooxygenase-2 inhibition: evidence from animal models of inflammation.
2001
Alzheimer's disease, inflammation and non-steroidal anti-inflammatory drugs.
2001
[COX-2 specific inhibitors: are NSAIDs and the stomach become reconcilied?].
2001 Apr
Gastrointestinal damage induced by celecoxib and rofecoxib in rats.
2001 Apr
Cyclo-oxygenase and lipoxygenase pathways in mast cell dependent-neurogenic inflammation induced by electrical stimulation of the rat saphenous nerve.
2001 Apr
[Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents].
2001 Apr 6
Rofecoxib as an alternative in aspirin hypersensitivity.
2001 Aug
Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits.
2001 Aug
Risk of cardiovascular events associated with selective COX-2 inhibitors.
2001 Aug 22-29
[Elderly patient with rheumatoid arthritis. Minimizing the peptic ulcer hemorrhage risk].
2001 Aug 9
The coxibs, selective inhibitors of cyclooxygenase-2.
2001 Aug 9
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
2001 Feb
Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor.
2001 Feb 15
Anti-inflammatory drugs, cyclooxygenases and other factors.
2001 Jan
Cyclooxygenase inhibitors: any reservations?
2001 Jan-Feb
Renal effects of COX-2-selective inhibitors.
2001 Jan-Feb
Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis.
2001 Jul
Stimulated release of arachidonic acid from rat liver cells by celecoxib and indomethacin.
2001 Jul
Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma.
2001 Jul
Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study.
2001 Jul
A new class of COX-2 inhibitors offer an alternative to NSAIDS in pain management after spinal surgery.
2001 Jul 1
[Safety of specific cyclo-oxygenase 2 inhibitors].
2001 Jul 28
[Clinical application of cyclooxygenase-2 inhibitors].
2001 Jun
Celecoxib-- the debate ranges on.
2001 Jun
Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis.
2001 Jun
[Results of the VIGOR study. Rofecoxib halves the complication rate].
2001 Jun 7
[Therapy of arthrosis. Life threatening gastrointestinal events can be reduced].
2001 Jun 7
Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, anti-inflammatory drugs with potential utility as anti-cancer agents.
2001 Mar
Involvement of cyclooxygenase-derived prostaglandin E2 and nitric oxide in the protection of rat pancreas afforded by low dose of lipopolysaccharide.
2001 Mar
Is rofecoxib safer than naproxen?
2001 Mar
[Cyclooxygenase inhibitors].
2001 Mar 17
Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis.
2001 May
[The selective Cox-2 inhibition by rofecoxib reduces risk of severe gastrointestinal complications of anti-inflammatory therapy by more than 50%].
2001 May
[The coxibs, third generation of non-steroidal anti-inflammatory agents].
2001 May-Jun
LC determination of rofecoxib in bulk and pharmaceutical formulations.
2001 Nov
COX-1 and COX-2 inhibitors.
2001 Oct
Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials.
2001 Oct
Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions.
2001 Sep
Tolerability of rofecoxib.
2001 Sep
Nephrotoxicity of selective COX-2 inhibitors.
2001 Sep
Ischemic preconditioning, the most effective gastroprotective intervention: involvement of prostaglandins, nitric oxide, adenosine and sensory nerves.
2001 Sep 21
How safe are your prescription pills?
2001 Sep 3
Arthritis: what it is, why you get it and how to stop the pain.
2001 Sep 3
Pain relief at a price. A blow to the heart?
2001 Sep 3
Celecoxib- and rofecoxib-induced delirium.
2001 Spring
Patents

Sample Use Guides

Osteoarthritis: the recommended starting dose of rofecoxib (VIOXX) is 12.5 mg once daily. Rheumatoid Arthritis: the recommended dose is 50 mg once daily. Management of Acute Pain and Treatment of Primary Dysmenorrhea: the recommended dose is 50 mg once daily. Acute Treatment of Migraine Attacks with or without aura: the recommended dose is 25 mg once daily.
Route of Administration: Oral
THP-1 human macrophages and peripheral blood mononuclear cells were incubated with rofecoxib (at 5, 10, 25 uM). The presence of rofecoxib (at high concentrations) significantly decreased expression of 27-hydroxylase and ABCA1, interfering with normal cholesterol outflow from macrophages.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:56:10 UTC 2021
Edited
by admin
on Fri Jun 25 21:56:10 UTC 2021
Record UNII
0QTW8Z7MCR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ROFECOXIB
HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
NSC-758705
Code English
ROFECOXIB [INN]
Common Name English
MK-966
Code English
TRM-201
Code English
VIOXX
Brand Name English
M01AH02
Code English
ROFECOXIB [MI]
Common Name English
NSC-720256
Code English
ROFECOXIB [MART.]
Common Name English
ROFECOXIB [USAN]
Common Name English
MK-0966
Code English
MK0966
Code English
ROFECOXIB [WHO-DD]
Common Name English
ROFECOXIB [VANDF]
Common Name English
4-(4-(METHYLSULFONYL)PHENYL)-3-PHENYL-2(5H)-FURANONE
Systematic Name English
ROFECOXIB [ORANGE BOOK]
Common Name English
ROFECOXIB [JAN]
Common Name English
4-(P-(METHYLSULFONYL)PHENYL)-3-PHENYL-2(5H)-FURANONE
Common Name English
ROFECOXIB [HSDB]
Common Name English
Classification Tree Code System Code
WHO-VATC QM01AH02
Created by admin on Fri Jun 25 21:56:10 UTC 2021 , Edited by admin on Fri Jun 25 21:56:10 UTC 2021
NCI_THESAURUS C80509
Created by admin on Fri Jun 25 21:56:10 UTC 2021 , Edited by admin on Fri Jun 25 21:56:10 UTC 2021
FDA ORPHAN DRUG 181703
Created by admin on Fri Jun 25 21:56:10 UTC 2021 , Edited by admin on Fri Jun 25 21:56:10 UTC 2021
LIVERTOX 858
Created by admin on Fri Jun 25 21:56:10 UTC 2021 , Edited by admin on Fri Jun 25 21:56:10 UTC 2021
WHO-ATC M01AH02
Created by admin on Fri Jun 25 21:56:10 UTC 2021 , Edited by admin on Fri Jun 25 21:56:10 UTC 2021
FDA ORPHAN DRUG 601917
Created by admin on Fri Jun 25 21:56:10 UTC 2021 , Edited by admin on Fri Jun 25 21:56:10 UTC 2021
Code System Code Type Description
DRUG BANK
DB00533
Created by admin on Fri Jun 25 21:56:10 UTC 2021 , Edited by admin on Fri Jun 25 21:56:10 UTC 2021
PRIMARY
EVMPD
SUB04261MIG
Created by admin on Fri Jun 25 21:56:10 UTC 2021 , Edited by admin on Fri Jun 25 21:56:10 UTC 2021
PRIMARY
NCI_THESAURUS
C1832
Created by admin on Fri Jun 25 21:56:10 UTC 2021 , Edited by admin on Fri Jun 25 21:56:10 UTC 2021
PRIMARY
EPA CompTox
162011-90-7
Created by admin on Fri Jun 25 21:56:10 UTC 2021 , Edited by admin on Fri Jun 25 21:56:10 UTC 2021
PRIMARY
IUPHAR
2893
Created by admin on Fri Jun 25 21:56:10 UTC 2021 , Edited by admin on Fri Jun 25 21:56:10 UTC 2021
PRIMARY
WIKIPEDIA
ROFECOXIB
Created by admin on Fri Jun 25 21:56:10 UTC 2021 , Edited by admin on Fri Jun 25 21:56:10 UTC 2021
PRIMARY
MERCK INDEX
M9647
Created by admin on Fri Jun 25 21:56:10 UTC 2021 , Edited by admin on Fri Jun 25 21:56:10 UTC 2021
PRIMARY Merck Index
FDA UNII
0QTW8Z7MCR
Created by admin on Fri Jun 25 21:56:10 UTC 2021 , Edited by admin on Fri Jun 25 21:56:10 UTC 2021
PRIMARY
PUBCHEM
5090
Created by admin on Fri Jun 25 21:56:10 UTC 2021 , Edited by admin on Fri Jun 25 21:56:10 UTC 2021
PRIMARY
CAS
162011-90-7
Created by admin on Fri Jun 25 21:56:10 UTC 2021 , Edited by admin on Fri Jun 25 21:56:10 UTC 2021
PRIMARY
ChEMBL
CHEMBL122
Created by admin on Fri Jun 25 21:56:10 UTC 2021 , Edited by admin on Fri Jun 25 21:56:10 UTC 2021
PRIMARY
HSDB
7262
Created by admin on Fri Jun 25 21:56:10 UTC 2021 , Edited by admin on Fri Jun 25 21:56:10 UTC 2021
PRIMARY
DRUG CENTRAL
2397
Created by admin on Fri Jun 25 21:56:10 UTC 2021 , Edited by admin on Fri Jun 25 21:56:10 UTC 2021
PRIMARY
INN
7768
Created by admin on Fri Jun 25 21:56:10 UTC 2021 , Edited by admin on Fri Jun 25 21:56:10 UTC 2021
PRIMARY
MESH
C116926
Created by admin on Fri Jun 25 21:56:10 UTC 2021 , Edited by admin on Fri Jun 25 21:56:10 UTC 2021
PRIMARY
RXCUI
232158
Created by admin on Fri Jun 25 21:56:10 UTC 2021 , Edited by admin on Fri Jun 25 21:56:10 UTC 2021
PRIMARY RxNorm
Related Record Type Details
EXCRETED UNCHANGED
AMOUNT EXCRETED
URINE
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
METABOLIC ENZYME -> INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC